Stockreport

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value– At the maximally effective dose, there were no cases of vomi [Read more]